CEREGENE
Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.
CEREGENE
Social Links:
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
2000-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.ceregene.com
Total Employee:
51+
Status:
Active
Contact:
(858)458-8800
Email Addresses:
[email protected]
Total Funding:
71.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Font Awesome Wordpress Plugins Sitelinks Search Box Organization Schema
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Current Advisors List
Current Employees Featured
Founder
Investors List
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Series D - Ceregene
Alta Partners
Alta Partners investment in Series C - Ceregene
Hamilton BioVentures
Hamilton BioVentures investment in Series C - Ceregene
MPM Capital
MPM Capital investment in Series C - Ceregene
Cell Genesys
Cell Genesys investment in Series C - Ceregene
California Technology Ventures
California Technology Ventures investment in Series C - Ceregene
Investor Growth Capital Limited
Investor Growth Capital Limited investment in Series C - Ceregene
Alta Partners
Alta Partners investment in Series B - Ceregene
solana customer support
solana customer support investment in Series B - Ceregene
California Technology Ventures
California Technology Ventures investment in Series B - Ceregene
Official Site Inspections
http://www.ceregene.com
- Host name: 172.67.177.5
- IP address: 172.67.177.5
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ceregene"
Ceregene - Crunchbase Company Profile & Funding
Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their โฆSee details»
Ceregene, Inc. Company Profile | San Diego, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Ceregene, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Ceregene 2025 Company Profile: Valuation, Investors, Acquisition ...
When was Ceregene founded? Ceregene was founded in 2000. Where is Ceregene headquartered? Ceregene is headquartered in San Diego, CA. What is the size of Ceregene? โฆSee details»
CEREGENE, INC โ California Technology Ventures
Ceregene, Inc. is a San Diego-based biotechnology company focused on the development and commercialization of gene therapies for the treatment of neurological disorders including โฆSee details»
Ceregene - Products, Competitors, Financials, Employees, โฆ
Ceregene's clinical program for Alzheimer's disease involves CERE-110, an AAV2-based vector expressing nerve growth factor (NGF). A fully enrolled multi- center, controlled Phase 2 study โฆSee details»
Ceregene Company Profile - Office Locations, Competitors ... - Craft
Ceregene is a biotechnology company focused on developing neurotrophic growth factor treatments for major neurodegenerative disorders using a proprietary gene delivery โฆSee details»
Ceregene, Inc. Overview | SignalHire Company Profile
Ceregene, Inc. is a private company that has been in the industry for 22 years. The position of the CEO is occupied by Jeffrey Ostrove. Its headquarters is located at San Diego, California, USA. โฆSee details»
Ceregene - Company Profile - Tracxn
Nov 5, 2024 Ceregene - Develops AAV-based therapies for neurodegenerative and eye disorders. Acquired by Sangamo BioSciences. Raised a total funding of $71.5M over 3 rounds โฆSee details»
Organization | Ceregene
Organization Overview. First Clinical Trial. 2004 NCT00087789. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Ceregene (www.ceregene.com) Active โฆSee details»
Ceregene, Inc. - Google Search
Ceregene, Inc. provides health care services. The Company designs and develops the treatment for major neurodegenerative disorders such as parkinsons, alzheimers, and huntingtons โฆSee details»
Ceregene - Contacts, Employees, Board Members, Advisors
Ceregene is a biotechnology company that treats neurodegenerative disorders using the delivery of nervous system growth factors. New. Resources. Advanced Search. Start Free Trial . Talk โฆSee details»
Ceregene, Inc.:Company Profile & Technical Research,Competitor โฆ
Ceregene is a company that provides Lampalizumab, Angiogenesis inhibitor, Medicine and more. Ceregene is headquartered in United States California. Ceregene was founded in 2000. and โฆSee details»
Ceregene - Overview, News & Similar companies | ZoomInfo.com
Who is Ceregene. Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegene rative disorders โฆSee details»
Gene Delivery Technology - Ceregene
Ceregeneโs AAV-based gene delivery technology provides a wide platform to develop treatments for many serious but different diseases, including Alzheimerโs Disease, Amyotrophic Lateral โฆSee details»
Science - Ceregene
Science at Ceregene Ceregene develops products that are intended to substantially improve the symptoms of terrible, debilitating diseases of the brain and eyes, and for the first time ever โฆSee details»
Ceregene, Inc. (Ceregene, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅ โฆ
He co-founded and served as Chairman of Ceregene, Inc., a gene therapy company acquired by Sangamo Therapeutics, Inc. in 2013. He served on the Board of Directors of Neon โฆSee details»
Pipeline - Ceregene
Ceregeneโs pipeline currently includes four major products at varying stages of development: CERE-110, CERE-120, CERE-130, and CERE-140. CERE-120 (AAV-NTN) CERE-120 is โฆSee details»
DNA organization offers clues for advancing stem cell therapy
3 days ago DNA organization offers clues for advancing stem cell therapy. by Iqbal Pittalwala, University of California - Riverside. Stem cells (shown as small balls) can be imagined to roll โฆSee details»
Ocular Disease - Ceregene
Ocular Diseases Ceregene is developing novel treatments for several ocular diseases in order to restore lost vision and prevent eventual blindness. Retinitis pigmentosa (RP) is one such โฆSee details»
Clinical Trials - Ceregene
Ceregene's clinical programs focus on developing pioneering new treatments for neurological disorders. We currently have a multi-center Phase 2 trial for Parkinson's disease in several โฆSee details»